Evercore ISI analyst Mark Mahaney has maintained their neutral stance on CDLX stock, giving a Hold rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Mark Mahaney has given his Hold rating due to a combination of factors, including Cardlytics’ recent financial performance and future outlook. The company showed better-than-expected results in Q4, with significant beats in key metrics such as Billings, Revenue, and Adjusted EBITDA. However, despite these positive results, management’s guidance for Q1 was less optimistic, indicating a slower-than-anticipated recovery in billings.
Moreover, while there are some positive signs, the path to achieving sustainably positive Adjusted EBITDA appears to be more prolonged and less straightforward than previously thought. The fundamentals in Q4 showed some weakening, with deceleration in both Billings and Revenue growth and a contraction in EBITDA margin. As a result, Mahaney has adjusted the price target downward, reflecting a more cautious outlook on the company’s near-term financial trajectory.
In another report released today, Craig-Hallum also maintained a Hold rating on the stock with a $3.00 price target.